Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with walter reed stage 2 human immunodeficiency virus infection: Results of ACTG protocol 042

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1170-1173

  Bartlett, John A ^a   Berend, Cindy ^b   Petroni, Gina R ^b   Ottinger, Janet ^b   Tyler, Douglas L ^b   Pettinelli, Carla ^b   Weinhold, Kent J ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2; ZIDOVUDINE;

ARTICLE; BLOOD TOXICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MONONUCLEAR CELL; MYALGIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0031691081     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515677     Document Type: Article

References (17)

1. Volberding P, Moody D, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immunodeficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24.
2. Lane HC, Siegel J, Rook A, et al. Use of interleukin-2 in patients with acquired immune deficiency syndrome. J Biol Response Modifiers 1984;2:512-6.
3. Schwartz D, Skowron G, Merigan T. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Def Syndr 1991;4:11-23.
4. Teppler H, Kaplan G, Smith K, Cameron P, Montana A, Meyn P. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:291-8.
5. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993;167:519-25.
6. Teppler H, Kaplan G, Smith K, Montana A, Meyn P, Cohn Z. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993;177:483-92.
7. McMahon DK, Armstrong JA, Huang XL, et al. A phase I study of subcutaneous recombinant in interleukin-2 patients with advanced HIV disease while on zidovudine. AIDS 1994;8:59-66.
8. Ramachandran R, Katzenstein D, Merigan T. Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. J Infect Dis 1994;170:1044-5.
9. Kovacs J, Baseler M, Dewar R, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-75.
10. Ramachandran R, Katzenstein DA, Winters MA, Kundu S, Merigan T. Polyethylene glycol-modified interleukin-2 and thymosin, in human immunodeficiency virus type 1 infection. J Infect Dis 1996;173: 1005-8.
11. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
12. Davey R, Chaitt D, Piscitelli S, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997;175:781-9.
13. Falloon J, Owen C, Metcalf J, Fyfe G, Lane HC. Indinvair and interleukin-2 in HIV: one year follow-up [abstract I 108]. In: Program and abstract of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
14. Jacobson E, Pilaro F, Smith K. Rational interleukin-2 therapy for HIV-positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93:10405-10.
15. Howell DN, Andreotti PE, Dawson JR, Cresswell P. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 1985;134:971-6.
16. + effector cells armed in vivo with cytophilic antibody. J Immunol 1989; 142:1177-82.
17. + lymphocytes from asymptomatic HIV-infected individuals inhibit HIV-1 replication. J Infect Dis 1995;172:964-73.